Introgen Therapeutics, Inc. Oral Health Alliance With Colgate-Palmolive Using Introgen's Molecular Therapies Announced
November 07 2005 - 11:35AM
PR Newswire (US)
$20 Million Transaction Will Target Treatment and Prevention of
Oral Cancer and Oral Premalignancies AUSTIN, Texas, Nov. 7
/PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (NASDAQ:INGN)
today reiterated the announcement of its alliance with
Colgate-Palmolive Co. (NYSE:CL) to develop and potentially market
oral health care products. Under the deal, Introgen will work
towards developing specialized formulations of its molecular
therapies to help prevent pre- cancerous conditions of the oral
cavity and oral cancer. Colgate-Palmolive purchased $20 million of
Introgen shares and has priority rights regarding products that may
be developed by the alliance. Introgen will focus on oral
formulations of its molecular therapeutics employing tumor
suppressors such as p53, mda-7, and FUS1. Introgen's academic
collaborators previously conducted a phase 1 clinical study using
INGN 234, a mouthwash formulation delivering the p53 tumor
suppressor for oral cancer prevention in patients diagnosed with
leukoplakia, a condition that can lead to oral cancer. Leukoplakia
is usually diagnosed by dentists and, according to the journal
Practical Periodontics and Aesthetic Dentistry, occurs in
approximately 3 percent of the adult population. "We are
enthusiastic about the opportunity to work with Colgate-Palmolive
to apply Introgen's molecular agents to develop oral care
products," stated David G. Nance, Chief Executive Officer of
Introgen. "We believe future commercial applications of therapeutic
genes will include topical formulations such as those developed for
oral use under the alliance with Colgate. The tissues lining the
oral cavity may be particularly well suited and accessible targets
for molecular therapies that can stop abnormal cell growth without
harming normal cells. We believe that repairing damaged cells and
safely eliminating malignant or pre-malignant cells from the mouth
could represent important therapies for dentists, oral health
professionals and oncology specialists to prevent and treat oral
diseases. We expect to investigate new formulations of oral rinses,
gels or other topically-applied products under the Colgate
alliance." Excluded from the alliance with Colgate are Introgen's
current portfolio of cancer product candidates, i.e. ADVEXIN, INGN
241, INGN 225, and INGN 401. Quarterly Conference Call
Additionally, Introgen announced that it has scheduled a conference
call to be held on November 9th to discuss the Colgate transaction
and the financial results of the quarter ended September 20, 2005
at 4:30 p.m. eastern time. The call may be accessed by dialing
1-877-616-4476 or 1-706-679-7372 or via Internet broadcast at
http://www.introgen.com/ . For those unable to listen to the
broadcast, the call will be archived at Introgen's Website at
http://www.introgen.com/ in the Investor Relations section.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused
on the discovery, development and commercialization of targeted
molecular therapies for the treatment of cancer and other diseases.
Introgen is developing molecular therapeutics, immunotherapies,
vaccines and nano-particle tumor suppressor therapies to treat a
wide range of cancers and hyper-proliferative disorders using tumor
suppressors, cytokines, proteins and genes. Introgen maintains
integrated research, development, manufacturing, clinical and
regulatory departments and operates multiple manufacturing
facilities including a commercial scale cGMP manufacturing
facility. For more information on Introgen Therapeutics, or for a
menu of archived press releases, please visit Introgen's Website
at: http://www.introgen.com/ Statements in this release that are
not strictly historical may be "forward-looking" statements,
including those relating to Introgen's future success with its
clinical development program for treatment of cancer or other
diseases and the development by Introgen Therapeutics, Inc. of its
molecular therapies targeted at oral cancer and pre-cancerous
conditions of the oral cavity in connection with the alliance with
Colgate-Palmolive. The actual results may differ from those
described in this release due to risks and uncertainties that exist
in Introgen's operations and business environment, including
Introgen's stage of product development and the limited experience
in the development of gene-based drugs in general, dependence upon
proprietary technology and the current competitive environment,
history of operating losses and accumulated deficits, reliance on
collaborative relationships, and uncertainties related to clinical
trials, the safety and efficacy of Introgen's product candidates,
the ability to obtain the appropriate regulatory approvals,
Introgen's patent protection and market acceptance, as well as
other risks detailed from time to time in Introgen's filings with
the Securities and Exchange Commission including its filings on
Form 10-K and Form 10-Q. Introgen undertakes no obligation to
publicly release the results of any revisions to any
forward-looking statements that reflect events or circumstances
arising after the date hereof. Contact: Introgen Therapeutics, Inc.
C. Channing Burke (512) 708 9310 Ext. 322 Email: DATASOURCE:
Introgen Therapeutics, Inc. CONTACT: C. Channing Burke of Introgen
Therapeutics, Inc., +1-512-708-9310 Ext. 322, or Web site:
http://www.introgen.com/
Copyright
Colgate Palmolive (NYSE:CL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Colgate Palmolive (NYSE:CL)
Historical Stock Chart
From Jul 2023 to Jul 2024